FDA reverses course and will review Moderna’s mRNA-based flu vaccine

Source: US news | The Guardian · Bias: Center Left

Summary

US drug regulator originally refused to consider application, fueling critics’ concern about alleged ‘anti-vaccine agenda’The Food and Drug Administration (FDA) reversed course on Wednesday and will now review Moderna’s application for the first mRNA-based flu vaccine after initially declining to consider it.Moderna announced that the US drug regulator will move forward with reviewing its updated flu vaccine application. The decision comes only a week after the agency turned down the company’s original filing, a move that had prompted criticism across the medical industry about potential changes in how the regulator is making decisions under the Trump administration. Continue reading...

Related Coverage

More Headlines From February 18, 2026

FDA reverses course and will review Moderna’s mRNA-based flu vaccine
US news | The Guardian

FDA reverses course and will review Moderna’s mRNA-based flu vaccine

Center Left

US drug regulator originally refused to consider application, fueling critics’ concern about alleged ‘anti-vaccine agenda’The Food and Drug Administration (FDA) reversed course on Wednesday and will now review Moderna’s application for the first mRNA-based flu vaccine after initially declining to consider it.Moderna announced that the US drug regulator will move forward with reviewing its updated flu vaccine application. The decision comes only a week after the agency turned down the company’s original filing, a move that had prompted criticism across the medical industry about potential changes in how the regulator is making decisions under the Trump administration. Continue reading...